Nanobodies are subject of investigation for several years and many studies were published targeting EGFR or HER2 overexpressing tumours, however mainly tumours with diameters of approximately 0.5–1 cm3, 23 or volumes of above 100 mm3 with tumour weights far beyond 100 mg3, 4, 23, 24. This evidence concerns the gene ERBB2 and neoplasm.